Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors

Journal of Investigative Dermatology

Volumn 122, Issue 6, 2004, Pages 1488-1494

  Wilgus, Traci A ^a   Breza Jr , Thomas S ^a   Tober, Kathleen L ^a   Oberyszyn, Tatiana M ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b 129 Hamilton Hall ^*  (United States)

Author keywords

Chemotherapy; Cyclooxygenase 2; Murine; Non melanoma skin cancer; Prostaglandin E2

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

EID: 2942585284     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.22606.x     Document Type: Article

References (31)

1. Ashton H, Beveridge GW, Stevenson CJ: Topical treatment of skin tumours with 5-fluorouracil. Br J Dermatol 82:207-209, 1970
2. Belisario JC: Topical use of 5-fluorouracil. Med J Aust 2:91, 1973
3. Berhane T, Halliday GM, Cooke B, Barnetson RS: Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 146:810-815, 2002
4. Breza T, Taylor R, Eaglstein WH: Noninflammatory destruction of actinic keratoses by fluorouracil. Arch Dermatol 112:1256-1258, 1976
5. Buckman SY, Gresham A, Hale R Hruza G, Anast J, Masferrer J, Pentland AP: COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer. Carcinogenesis 19:723-729, 1998
6. Chu E, Callender MA, Farrell MP, Schmitz JC: Thymidylate synthase inhibitors as anticancer agents: From bench to bedside. Cancer Chemother Pharmacol 52 (Suppl. 1):S80-S89, 2003
7. Dillaha CJ, Jansen GT, Honeycutt WM, Bradford AC: Selective cytotoxic effect of topical 5-Fluorouracil. Arch Dermatol 88:247-256, 1963
8. Falkson G, Schulz EJ: Skin changes in patients treated with 5-fluorouracil. Br J Dermatol 74:229-236, 1962
9. Fischer SM, Conti CJ, Viner J, Aldaz CM, Lubet RA: Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis 24:945-952, 2003
10. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, Conti CJ: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25:231-240, 1999
11. Gupta AK, Weiss JS, Jorizzo JL: 5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. Skin Ther Lett 6:1-4, 2001
12. Heidelberger C, Chaudhuri NK, Danneberg R et al: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179:663-666, 1957
13. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397-11403, 2000
14. Kishi K, Petersen S, Petersen C, et al: Preferential enhancement of tumor radio-response by a cyclooxygenase-2 inhibitor. Cancer Res 60:1326-1331, 2000
15. Koki A, Khan NK, Woerner BM, et al: Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol 507:177-184, 2002
16. Liang L, Hu D, Liu W, Williams JR Okunieff P, Ding I: Celecoxib reduces skin damage after radiation: Selective reduction of chemokine and receptor mRNA expression in irradiated skin but not in irradiated mammary tumor. Am J Clin Oncol 26:S114-S121, 2003
17. Milas L, Mason KA, Crane CH, Liao Z, Masferrer J: Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology (Huntingt) 17:15-24, 2003
18. Mizutani Y, Kamoi K, Ukimura O, Kawauchi A, Miki T: Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. J Urol 168:2650-2654, 2002
19. Ogino M: Indomethacin augmented antitumor activity of 5-fluorouracil in Meth-A induced mice. Int J Clin Oncol 1:75-79, 1996
20. Ogino M, Hanazono M: Indomethacin preferentially augments 5-fluorouracil cytotoxicity in Colon 26 tumors by increasing the intracellular inflow of 5-fluorouracil. Int J Clin Oncol 4:22-25, 1999
21. Ogino M, Minoura S: Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human uterine cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents. Int J Clin Oncol 6:84-89, 2001
22. Orengo IF, Gerguis J, Phillips R, Guevara A, Lewis AT, Black HS: Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: A study in the hairless mouse model. Arch Dermatol 138:751-755, 2002
23. Pearlman DL, Youngberg B, Engelhard C: Weekly pulse dosing schedule of fluorouracil: A new topical therapy for psoriasis. J Am Acad Dermatol 15:1247-1252, 1986
24. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R: Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 20:1939-1944, 1999
25. Salim A, Leman JA, McColl JH, Chapman R, Morton CA: Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 148:539-543, 2003
26. Sander CA, Pfeiffer C, Kligman AM, Plewig G: Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol 36:236-238, 1997
27. Tsuji T, Nakagawa K, Hamada T: Different effects of topically applied 5-fluorouracil on hairy and hairless mice. Clin Exp Dermatol 9:574-582, 1984
28. Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM: Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog 38:49-58, 2003a
29. Wilgus TA, Koki AT, Zweifel BS, Rubal PA, Oberyszyn TM: Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Mol Carcinog 38:33-39, 2003b
30. Wilgus TA, Ross MS, Parrett ML, Oberyszyn TM: Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins Other Lipid Mediat 62:367-384, 2000
31. Yao M, Kargman S, Lam EC, et al: Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 63:586-592, 2003